Cost-effectiveness of insulin detemir versus NPH for type I diabetes patients in a German setting. A modeling evaluation based upon results from a meta-analysis

被引：0

作者：

Kotchie, R. ^{[1
]}

Scheijbeler, H. ^{[1
]}

Aagren, M. ^{[2
]}

Nielsen, S. ^{[2
]}

Valentine, W. J. ^{[3
]}

Goodall, G. ^{[3
]}

机构：

[1] IMS Hlth, London, England

[2] Novo Nordisk AS, Virum, Denmark

[3] IMS Hlth, Basel, Switzerland

来源：

VALUE IN HEALTH | 2007年 / 10卷 / 06期

关键词：

D O I：

10.1016/S1098-3015(10)64858-9

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A222 / A222

页数：1

共 50 条

[1] Cost-effectiveness of insulin detemir versus NPH for type I diabetes patients in an Italian setting. A meta-analysis
Aristides, M.
Kotchie, R.
Nielsen, S.
Aagren, M.
Valentine, W. J.
Goodall, G.
[J]. VALUE IN HEALTH, 2007, 10 (06) : A260 - A260
[2] Cost-effectiveness of detemir versus NPH for type I diabetes patients treated with basal-bolus therapy in a Belgium setting. A modeling evaluation based on results from a meta-analysis of three clinical trials
Scheilbeler, H.
Aagren, M.
Nielsen, S.
Goodall, G.
Kotchie, R.
Valentine, W. J.
[J]. VALUE IN HEALTH, 2007, 10 (06) : A261 - A261
[3] Cost-utility of insulin detemir versus NPH for type 1 diabetes patients treated with basal-bolus therapy in a French setting. A modeling evaluation based on results from a meta-analysis of three clinical trials
Schejbeler, H.
Aagren, M.
Nielsen, S.
Valentine, W. J.
Goodall, G.
Kotchie, R.
[J]. VALUE IN HEALTH, 2007, 10 (06) : A268 - A268
[4] Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis
Tunis, Sandra L.
Minshall, Michael E.
Conner, Christopher
McCormick, John I.
Kapor, Jovana
Yale, Jean-Francois
Groleau, Danielle
[J]. CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (05) : 1273 - 1284
[5] Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/-bolus therapy for Type 1 diabetes in a UK setting. An economic evaluation based on a meta-analysis of four clinical trials
Roze, S
Palmer, AJ
Valentine, WJ
Smith, IC
Wittrup-Jensen, K
[J]. DIABETOLOGIA, 2004, 47 : A345 - A345
[6] Cost-effectiveness analysis of insulin detemir compared to NPH insulin in patients with type-2 diabetes in the United Kingdom
Smith, I
Palmer, AJ
Roze, S
Kennedy-Martin, T
[J]. VALUE IN HEALTH, 2004, 7 (06) : 735 - 736
[7] Cost-effectiveness of detemir based basal-bolus therapy versus NPH for type 1 diabetes in a Spanish setting
Ray, J. A.
Valentine, W. J.
Goodall, G.
Aagren, M.
Kotchie, R. W.
[J]. DIABETOLOGIA, 2007, 50 : S428 - S428
[8] CLINICAL AND COST OUTCOMES OF TREATMENT WITH INSULIN GLARGINE VERSUS INSULIN DETEMIR IN INSULIN NAIVE TYPE 2 DIABETES PATIENTS: COST-EFFECTIVENESS ANALYSIS IN THE KAZAKHSTAN SETTING
Kostyuk, A.
Akanov, A.
Almadiyeva, A.
[J]. VALUE IN HEALTH, 2016, 19 (03) : A203 - A204
[9] SHORT-TERM COST-EFFECTIVENESS ANALYSIS OF INSULIN DETEMIR VERSUS INSULIN NEUTRAL PROTAMINE HAGEDORN (NPH) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN SPAIN
Ramirez de Arellano, A.
Morales, C.
De Luis, D.
Ferrario, M. G.
Lizan, L.
[J]. VALUE IN HEALTH, 2014, 17 (07) : A343 - A343
[10] Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UK
McEwan, Phil
Poole, Chris D.
Tetlow, Tony
Holmes, Paul
Currie, Craig J.
[J]. CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 : S7 - S19

← 1 2 3 4 5 →